Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:314 |
Name | tenosynovial giant cell tumor |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation benign neoplasm organ system benign neoplasm musculoskeletal system benign neoplasm connective tissue benign neoplasm bone benign neoplasm benign giant cell tumor tenosynovial giant cell tumor |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01207492 | Phase II | Nilotinib | Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor | Active, not recruiting | USA | 0 |
NCT02471716 | Phase Ib/II | Cabiralizumab | Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor | Completed | USA | POL | NLD | GBR | FRA | 1 |
NCT02673736 | Phase I | AC708 | A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor | Terminated | USA | 0 |
NCT04526704 | FDA approved | Pexidartinib | Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib (PLX3397) | Completed | USA | NLD | ITA | HUN | ESP | AUS | 1 |
NCT04938180 | Phase II | AMG 820 | A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients | Terminated | POL | HUN | 1 |
NCT05059262 | Phase III | Vimseltinib | Phase 3 Study of Vimseltinib for Tenosynovial Giant Cell Tumor (MOTION) | Active, not recruiting | USA | POL | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | AUS | 1 |
NCT05349643 | Phase II | AMB-05X | A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT | Completed | USA | NLD | AUS | 0 |
NCT05417789 | Phase III | Emactuzumab | Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) (TANGENT) | Recruiting | USA | NLD | ITA | ESP | CHE | 1 |
NCT05804045 | Phase III | ABSK021 | Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor | Active, not recruiting | USA | POL | NLD | ITA | ESP | CAN | 1 |